Friday the 13th has turned into a horror story for Australian biotech Immutep, whose share price collapsed after it abandoned a pivotal trial of its lead drug. Immutep's ASX-listed stock fell more ...
Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results